Key Points
- EVP George Lloyd sold 110,000 shares of Royalty Pharma at an average price of $39.77 on Dec. 3 for proceeds of $4,374,700, cutting his stake by 50% (disclosed in an SEC filing).
- Q3 results showed EPS of $1.17 (beat by $0.06) while revenue of $609.29M missed expectations of $765.01M, and analysts maintain a consensus "Moderate Buy" with a $46 price target.
- The stock trades near $39.70 with a 52‑week range of $24.05–$41.24 and a market cap of ~$22.9B; the company announced a quarterly dividend of $0.22 (annualized $0.88, ~2.2% yield).
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP George Lloyd sold 110,000 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $39.77, for a total transaction of $4,374,700.00. Following the completion of the sale, the executive vice president owned 110,000 shares of the company's stock, valued at approximately $4,374,700. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Royalty Pharma Stock Up 1.5%
Royalty Pharma stock opened at $39.73 on Friday. Royalty Pharma PLC has a fifty-two week low of $24.05 and a fifty-two week high of $41.24. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. The firm's 50-day simple moving average is $37.86 and its 200 day simple moving average is $36.34. The stock has a market cap of $22.93 billion, a PE ratio of 30.10, a price-to-earnings-growth ratio of 2.06 and a beta of 0.47.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The firm had revenue of $609.29 million for the quarter, compared to analysts' expectations of $765.01 million. Research analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.
Royalty Pharma Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $0.88 annualized dividend and a yield of 2.2%. Royalty Pharma's payout ratio is currently 66.67%.
Institutional Trading of Royalty Pharma
A number of institutional investors have recently modified their holdings of the business. Smartleaf Asset Management LLC grew its position in shares of Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 790 shares in the last quarter. USA Financial Formulas bought a new position in Royalty Pharma in the 2nd quarter worth about $32,000. Financial Consulate Inc. bought a new position in Royalty Pharma in the 3rd quarter worth about $35,000. Summit Securities Group LLC purchased a new position in Royalty Pharma during the 1st quarter valued at about $36,000. Finally, WPG Advisers LLC bought a new stake in shares of Royalty Pharma during the first quarter valued at about $39,000. 54.35% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several brokerages have recently issued reports on RPRX. The Goldman Sachs Group began coverage on Royalty Pharma in a research report on Tuesday, September 30th. They set a "buy" rating and a $42.00 target price for the company. Morgan Stanley decreased their price objective on shares of Royalty Pharma from $55.00 to $54.00 and set an "overweight" rating for the company in a report on Friday, October 10th. Wall Street Zen cut shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 28th. TD Cowen lowered shares of Royalty Pharma from a "strong-buy" rating to a "hold" rating in a research note on Monday, November 17th. Finally, Weiss Ratings cut shares of Royalty Pharma from a "buy (b-)" rating to a "hold (c+)" rating in a report on Saturday, October 25th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Royalty Pharma has an average rating of "Moderate Buy" and a consensus price target of $46.00.
Read Our Latest Research Report on RPRX
Royalty Pharma Company Profile
(
Get Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
